NCT06974110 2026-04-15
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
Phase 1 Recruiting
Clinical Trials
34 trialsNCT04920032 2026-04-13
Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas
University of California, Irvine
Phase 1 Recruiting
NCT05379595 2026-04-13
OrigAMI-1
Janssen Research & Development, LLC
Phase 1/2 Recruiting
NCT06662786 2026-04-13
OrigAMI-2
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06750094 2026-04-13
OrigAMI-3
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT05863195 2026-03-23
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT04657068 2026-03-18
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma Ltd
Phase 1/2 Recruiting
NCT07011576 2026-03-18
FRUITFUL
SCRI Development Innovations, LLC
Phase 2 Recruiting
NCT05239741 2026-03-10
MK-3475-C66
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT04230187 2026-03-05
TRIBE-C
Sun Yat-sen University
Phase 3 Recruiting
NCT07389265 2026-02-05
CAPRI-3 GOIM
University of Campania Luigi Vanvitelli
Phase 3 Recruiting
NCT06792695 2026-01-20
CANTOR
AstraZeneca
Phase 2 Recruiting
NCT04689347 2026-01-12
5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 1/2 Recruiting
NCT06586515 2025-12-22
MOONRAY-01
Eli Lilly and Company
Phase 1 Recruiting
NCT05959356 2025-12-17
CEIL
Sun Yat-sen University
Phase 2 Recruiting
NCT06714357 2025-12-17
VICTORIA
National Cancer Institute, Naples
Phase 2 Recruiting
NCT05391126 2025-12-16
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
University of Kentucky
Phase NA Recruiting
NCT05008809 2025-12-12
AIO-KRK-0418
Charite University, Berlin, Germany
Phase 3 Recruiting
NCT04329494 2025-12-10
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT06733038 2025-12-08
AtezoTRIBE2
Gruppo Oncologico del Nord-Ovest
Phase 3 Recruiting
NCT04776655 2025-10-02
LIBImAb
Azienda USL Reggio Emilia - IRCCS
Phase 3 Recruiting
NCT05571644 2025-07-23
OPTICAL-2
Sun Yat-sen University
Phase 2 Recruiting
NCT02885753 2025-07-09
OSCAR
Federation Francophone de Cancerologie Digestive
Phase 3 Recruiting
NCT04861558 2025-05-30
EFFIPEC
Uppsala University
Phase 3 Recruiting
NCT03401294 2025-05-09
CONVERSION
University of Saskatchewan
Phase 2 Recruiting
NCT06547203 2024-08-09
Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study
Sun Yat-sen University
Phase 2 Recruiting
NCT06509126 2024-07-19
IMPROVE-2
National Cancer Institute, Naples
Phase 3 Recruiting
NCT05462236 2024-07-09
MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer
AUM Biosciences Pte Ltd
Phase 2 Recruiting
NCT05229003 2024-07-03
Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC
Fudan University
Phase 2 Recruiting
NCT05954078 2024-05-20
Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer
Fudan University
Phase 3 Recruiting
NCT06202001 2024-04-02
Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2 Recruiting
NCT06321081 2024-03-20
ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
Beijing Hospital
Phase 2 Recruiting
NCT06242067 2024-02-05
BEV-TASIRI
Qilu Hospital of Shandong University
Phase 2 Recruiting
NCT05962502 2023-08-31
Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy
Sun Yat-sen University
Phase 2 Recruiting